Recently, FOTAI Pharma announced that its drugs Alyftrek® and Trikafta® have received label expansion approval from the U.S. Food and Drug Administration (FDA).

老虎证券2026/04/01 11:49

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This important development will significantly expand the range of people eligible for the two medications, and it is expected to grant treatment opportunities to about 95% of cystic fibrosis (CF) patients in the United States. This label expansion marks another breakthrough for Vertex Pharmaceuticals in the field of CF treatment, offering new hope to a broader patient population.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Recently, FOTAI Pharma announced that its drugs Alyftrek® and Trikafta® have received label expansion approval from the U.S. Food and Drug Administration (FDA).

You may also like

Crypto prices